GSTM1 and schizophrenia: Transcriptomic analysis of Hb-enriched samples from individuals with SCZD and neurotypical controls revealed both shared and unique molecular changes in Hb compared to other brain regions, providing further support that the Hb is a promising therapeutic target for treating neuropsychiatric disorders.